N/A
N=51
Target Engagement for Oxytocin: Dose Ranging Study
Schizophrenia Spectrum
Bottom Line
View on ClinicalTrials.gov: NCT02498236 ↗Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Jan 2019
Primary outcome: Primary: Mu Suppression on EEG — -0.0907; -0.0632; -0.0542; -0.1153 log10 transformed ratio (Hz)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Intranasal Oxytocin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Jul 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mu Suppression on EEG |
-0.0907; -0.0632; -0.0542; -0.1153; -0.1333; -0.0459 | — |
| PRIMARY Pupil Dilation While Observing Faces |
.0074; .0347; -.0089; .0153; -.0011; .0103 | — |
Summary
This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two proposed measures of target engagement in brain. The targets are (1) the suppression of a particular wave form (mu) on the electroencephalogram (EEG) while subjects observe a socially relevant form of motion and (2) pupil dilation will subjects identify faces showing different emotions.
Eligibility Criteria
Inclusion Criteria
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Able to cooperate with study procedures
Exclusion Criteria
- Serious medical condition or substance use
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT02498236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.